London, April 1, 2022: In accordance with previous announced information, ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"), a pharmaceutical company with a strategic focus on specialty pharmaceuticals and specialty & hospital generics in Europe, today welcomes Steffen Wagner as its new CEO.
Steffen joins from STADA, where he was a member of the Global Executive Committee and responsible for European Markets. Steffen is a medical doctor by training, has previously held senior roles with Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. He brings extensive international pharma experience that will be highly valuable in driving ADVANZ PHARMA’s continued journey to be the partner of choice for commercialising specialty pharmaceuticals and specialty & hospital generics in Europe.
Steffen was appointed together with several other recent senior leadership hires as ADVANZ PHARMA now enters into the next phase of its growth journey. These appointments include new CFO Andreas Stickler who joined from Merck KGaA and Susanna El-Armale who joined as Chief Corporate Development Officer from Theramex.
Steffen Wagner said: “This is a hugely exciting time to be joining ADVANZ PHARMA. It is a great platform on which we can build to achieve our vision to be a partner of choice in specialty pharmaceuticals in Europe. We will further expand the commercial footprint and accelerate growth via Mergers & Acquisitions and, Business Development & Licensing, and product launches. I am looking forward to working with my ADVANZ PHARMA colleagues and helping to improve patients’ lives by providing the critical medicines they depend on.”